>>Countdown to our free event: Meet the Real Money Pros: Market Strategies for 2012

NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS

Abercrombie & Fitch ( ANF) cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 32% over the past 11 months.

Aeropostale ( ARO) upgraded at Goldman from Sell to Neutral. The company can expand margins in the coming quarter.

Amedisys ( AMED) downgraded to sell at TheStreet Ratings.

American Tower ( AMT) numbers adjusted at Citigroup. Shares of AMT now seen reaching $65. Estimates lowered on FX headwinds. Buy rating.

American Tower estimates, target raised at JP Morgan. Shares of AMT now seen reaching $62. Estimates also increased on Core and Sprint MLA.

AmerisourceBergen ( ABC) estimates increased at UBS. ABC estimates increased through 2013. Positive operating trends. Maintain $47 price target and Buy rating.

Ann ( ANN) downgraded at Goldman from Neutral to Sell. Margins are peaking and the company is leveraged to slower macro growth.

Archer Daniels Midland ( ADM) numbers cut at Morgan Stanley. Shares of ADM now seen reaching $37. Estimates also reduced, given lower oilseed margins. Overweight rating.

Atmel ( ATML) downgraded at Needham from Strong Buy to Buy. Company could face inventory rebalancing in the next couple of quarters.

Atmel upgraded to buy at TheStreet Ratings.

Autodesk ( ADSK) target cut at UBS to $43. VARs continue to plod through a sluggish economic environment. Buy rating.

Baker Hughes ( BHI) numbers cut at Credit Suisse. Shares of BHI now seen reaching $80. Estimates also reduced, given lower expected North American pricing. Outperform rating.

Baker Hughes estimates increased at Sterne Agee. BHI estimates raised through 2012. Bullish rig count forecast. Maintain $71 price target and Buy rating.

Baker Hughes estimates, target cut at UBS. Shares of BHI now seen reaching $82. Estimates also increased as overall story is still in on track despite a sloppy 3Q. Buy rating.

Catalyst Health ( CHSI) numbers lowered at Credit Suisse. Shares of CHSI now seen reaching $62. Estimates also cut, to match the company's new guidance. Outperform rating.

Caterpillar ( CAT) rated new Overweight at Morgan Stanley. Valuation call, based on a $125 price target.

CME Group ( CME) numbers lowered at Jefferies. CME estimates were cut through 2012. Volume has moderates and expenses could be back on the rise. Buy rating and new $297 price target.

CME Group estimates lowered at UBS through 2012. MF Global bankruptcy may be a blow to the futures industry as a whole. Buy rating.

Corning ( GLW) downgraded at JP Morgan from Neutral to Underweight. Consumer risks are mounting.

Deere ( DE) rated new Underweight at Morgan Stanley. Company faces slower growth and margin pressures. $74 price target.

Diamond Foods ( DMND) downgraded at BofA/Merrill from Buy to Neutral. $65 price target. Estimates also cut, as the Pringles acquisition has been delayed.

Discovery Communications ( DISCA) numbers increased at UBS. Shares of DISCA now seen reaching $43. Estimates also raised as Netflix deal more accretive than expectations. Neutral rating.

Emerson Electric ( EMR) target increased at UBS to $51. Positive outlook despite challenging macro. Maintain Neutral rating.

Emerson Electric estimates, target cut at Sterne Agee. Shares of EMR now seen reaching $54. Estimates also lowered on slower expected global growth. Neutral rating.

EOG Resources ( EOG) estimates increased at UBS through 2012. 3Q beats on higher than expected natural gas and NGL production. Neutral rating.

Fidelity ( FIS) estimates, target lowered at Oppenheimer. FIS estimates were cut through 2012. EBITDA growth is slowing. Outperform rating and new $32 price target.

FXCM ( FXCM) upgraded at Citigroup from Sell to Neutral. $11.25 price target. With the recent downdraft we see a more balanced risk/reward.

HCA ( HCA) estimates, target raised at Credit Suisse. Shares of HCA now seen reaching $27, according to Credit Suisse. Estimates also increased, given solid volume growth and cost cuts. Outperform rating.

Impax Laboratories ( IPXL) numbers cut at Goldman. Shares of IPXL now seen reaching $18. Estimates also reduced, given lower expected Adderall XR sales. Sell rating.

Intrepid Potash ( IPI) rated new Neutral at UBS. $28 price target. Significant growth, but at a fair price.

IPG Photonics ( IPGP) upgraded at Needham from Hold to Buy. $60 price target. Company has solid visibility.

Lamar Advertising ( LAMR) numbers cut at Benchmark. Shares of LAMR now seen reaching $18. Estimates also reduced, as the outdoor advertising market has stalled. Hold rating.

MEMC Electronic Materials ( WFR) numbers lowered at Citigroup. Shares of WFR now seen reaching $10. Estimates also lowered on softer wafer volumes/pricing. Buy rating.

MetroPCS Communications ( PCS) estimates lowered at Citigroup through 2012. Smartphone strategy may be misaligned with its historical success as a low cost provider. Neutral rating.

MetroPCS upgraded at JP Morgan from Neutral to Overweight. Better than expected 3Q11 subscriber performance which sets a base line for the business in its typically weakest quarter.

Monsanto ( MON) rated new Neutral at UBS. $72 price target. Stock valuation stretched to the limit.

Myriad Genetics ( MYGN) upgraded at Ticonderoga from Neutral to Buy. $25 price target. BRAC Analysis continues to perform well.

NII Holdings ( NIHD) estimates, target cut at Citigroup. Shares of NIHD now seen reaching $45. Estimates also lowered on 3G opex costs. Buy rating.

Nike ( NKE) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction List. Stock usually performs well in an Olympic year.

OpenTable ( OPEN) downgraded at BofA/Merrill from Buy to Neutral. Valuation call, based on a $48 price target.

OpenTable downgraded at Morgan Keegan from Outperform to Market Perform. $39 price target. Slower macro growth could weigh on earnings.

OpenTable estimates, target cut at Citigroup. Shares of OPEN now seen reaching $67. Estimates also lowered on removal of spotlight revenue and restaurant industry macro weakness. Buy rating.

OpenTable estimates, target reduced at Oppenheimer. Shares of OPEN now seen reaching $54, according to Oppenheimer. Estimates also cut, given slower realized growth. Outperform rating.

Oshkosh Truck ( OSK) upgraded at Benchmark from Hold to Sell. $20 price target. Consensus expectations have come down to a reasonable level.

Oshkosh downgraded at Sterne Agee from Neutral to Underperform. $16 price target. Defense business remains weak and it will likely be another year of transition for the commercial division.

Pinnacle West ( PNW) estimates increased at UBS through 2011. AZ Sun plan continues to gain traction. Maintain $45 price target and Neutral rating.

Praxair ( PX) downgraded at Argus from Buy to Hold. Valuation call.

Ritchie Bros. ( RBA) upgraded at Baird from Neutral to Outperform. $25 price target. Earnings should bounce back in the fourth quarter, due to a calendar shift.

Rowan ( RDC) estimates, target reduced at Jefferies. RDC estimates were cut through 2012. Company is facing higher costs. Buy rating and new $48 price target.

SM Energy ( SM) numbers cut at Jefferies. Shares of SM now seen reaching $110. Estimates also reduced, as growth is slowing outside of Eagle Ford. Buy rating.

Tenet Healthcare ( THC) numbers boosted at Credit Suisse. Shares of THC now seen reaching $6. Estimates also upped, given higher expected near-term growth. Outperform rating.

Texas Roadhouse ( TXRH) downgraded at Credit Suisse from Outperform to Neutral. $16.50 price target. Company has limited pricing power.

Thoratec ( THOR) estimates increased at UBS through 2012. Guidance elevated on margins. Maintain $39 price target and Buy rating.

Treehouse Foods ( THS) downgraded at Wells from Outperform to Market Perform. Valuation call.

Triumph ( TGI) estimates, target raised at Credit Suisse. Shares of TGI now seen reaching $68. Estimates also increased, as the company remains leveraged to the aerospace cycle. Outperform rating.

Under Armour ( UAUA) upgraded at Goldman from Neutral to Buy. Brand momentum can help drive margin growth.

US Cellular ( USM) downgraded at Morgan Stanley from Equal-weight to Underweight. $35 price target. Company is facing increased competition.

Westlake Chemical ( WLK) estimates cut at UBS through 2012. Margin squeeze on polyolefins. Maintain $45 price target and Neutral rating.

>To submit a news tip, email: tips@thestreet.com.

RELATED STORIES:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Why You Can’t 'Uberfy' a Marketplace

Why You Can’t 'Uberfy' a Marketplace

Close the Book on Barnes & Noble

Close the Book on Barnes & Noble

No Clear Rhyme or Reason to Yahoo!’s M&A Strategy to Date

No Clear Rhyme or Reason to Yahoo!’s M&A Strategy to Date

Jim Cramer's 'Mad Money' Recap: Let the Good Times Roll

Jim Cramer's 'Mad Money' Recap: Let the Good Times Roll

Jim Cramer's 'Mad Money' Recap: Stocks That Stand the Test of Time

Jim Cramer's 'Mad Money' Recap: Stocks That Stand the Test of Time